Johnson & Johnson

Key catalysts

• Innovative Medicine portfolio

  Growth from newer and expanding oncology, immunology, and neuroscience medicines can offset erosion in mature products.

• MedTech procedure growth

  Higher procedure volumes and adoption of newer cardiovascular, surgery, orthopaedics, and vision technologies can support MedTech growth.

• Pipeline and indication expansion

  Regulatory approvals, label expansions, and clinical readouts across medicine and MedTech can create additional durable revenue streams.

Principal risks

• Talc litigation

  Pending talc claims create uncertain legal costs, potential judgments, and reputational exposure that may persist despite defense and resolution efforts.

• Exclusivity and pricing pressure

  Biosimilar or generic competition, government price negotiations, and payer pressure can reduce sales and margins for key medicines.

• Clinical and regulatory execution

  Pipeline assets and medical devices may fail trials, face approval delays, encounter safety findings, or fall short of commercial adoption expectations.

Johnson & Johnson reported results for its fiscal first quarter ended March 29, 2026, with contributions from Innovative Medicine and MedTech and an outlook centered on portfolio growth, pipeline execution, and operational investment.

Valuation interpretation

• Valuation should separate the growth and patent profiles of Innovative Medicine from the procedure-driven economics of MedTech.
• A durability premium depends on pipeline replacement of mature products and should be tempered by litigation and regulatory uncertainty.